What is the appropriate unfractionated heparin infusion regimen, including bolus dose, infusion rate, and activated partial thromboplastin time (aPTT) monitoring, for an adult with acute pulmonary embolism who has no contraindications to anticoagulation and normal renal function?

Unfractionated Heparin Infusion for Acute Pulmonary Embolism

For an adult with acute PE and normal renal function, initiate unfractionated heparin with an 80 units/kg IV bolus followed by 18 units/kg/hour continuous infusion, targeting an aPTT of 1.5-2.5 times control (or 60-85 seconds absolute range). This weight-based approach is superior to fixed dosing and is supported by both FDA labeling and multiple clinical guidelines 1, 2, 3.

Initial Dosing Regimen

Weight-based dosing is the standard of care:

• Bolus dose: 80 units/kg IV push 1, 2
• Initial infusion rate: 18 units/kg/hour 1, 2
• Alternative FDA-approved regimen: 5,000 units bolus followed by 20,000-40,000 units/24 hours (approximately 1,000-1,667 units/hour), though this is less precise 3

The weight-based nomogram has been validated to achieve therapeutic anticoagulation more rapidly than fixed-dose regimens 2. The British Thoracic Society guidelines also support weight-adjusted dosing (80 units/kg bolus, 18 units/kg/hour) over standard fixed dosing (5,000-10,000 units bolus, 1,300 units/hour) 4.

aPTT Monitoring Protocol

Check the first aPTT 4-6 hours after initiating therapy 4, 3. The FDA label specifies checking aPTT approximately every 4 hours initially when using continuous infusion 3.

Target therapeutic range:

• aPTT ratio: 1.5-2.5 times control 4, 3
• Absolute aPTT: 45-75 seconds (British Thoracic Society) or 60-85 seconds (some protocols) 4, 1
• This corresponds to anti-Factor Xa levels of 0.3-0.7 units/mL 1, 2

Subsequent monitoring intervals:

• After any dose adjustment: 6-10 hours later 4
• Once therapeutic: Daily 4
• FDA guidance: Continue monitoring approximately every 4 hours until stable, then at appropriate intervals 3

Dose Adjustment Algorithm

Use a structured nomogram for aPTT-based adjustments 2. The American Heart Association provides this validated protocol:

• aPTT <35 seconds (<1.2× control): 80 units/kg bolus, increase infusion by 4 units/kg/hour 2
• aPTT 35-45 seconds (1.2-1.5× control): 40 units/kg bolus, increase infusion by 2 units/kg/hour 2
• aPTT 46-70 seconds (1.5-2.3× control): No change 2
• aPTT 71-90 seconds (2.3-3× control): Decrease infusion by 2 units/kg/hour 2
• aPTT >90 seconds (>3× control): Hold infusion for 1 hour, then decrease by 3 units/kg/hour 2

Recheck aPTT 6 hours after each adjustment 2.

Critical Clinical Considerations

Achieving therapeutic anticoagulation within 24 hours is essential. Early subtherapeutic aPTT has historically been associated with increased recurrent thromboembolism risk, though more recent data with adequate initial dosing (≥1,250 units/hour) show this relationship may be less pronounced 5, 6. However, the 2025 data demonstrate that higher time in therapeutic range (TTR) within the first 72 hours correlates with improved 30-day and one-year mortality 7.

Do not cap initial doses in obese patients. Standard weight-based protocols that specify maximum initial bolus or infusion rates cause significant delays in achieving therapeutic anticoagulation in obese and morbidly obese patients 8, 9. For patients with BMI ≥30 kg/m², use actual body weight without capping, or consider adjusted body weight formulas: IBW + 0.3(ABW - IBW) or IBW + 0.4(ABW - IBW) 9.

Baseline and ongoing laboratory monitoring:

• Before initiation: aPTT, INR, platelet count, hemoglobin/hematocrit 3
• During therapy: Periodic platelet counts (monitor for HIT), hematocrit, occult blood in stool 3

Duration and Transition to Oral Anticoagulation

Continue heparin for at least 5 days AND until INR ≥2.0 for 2 consecutive days when transitioning to warfarin 4, 3. Start warfarin on day 1 or 2 of heparin therapy 4. For non-warfarin oral anticoagulants, stop heparin infusion immediately after administering the first dose, or for intermittent IV heparin, start the oral agent 0-2 hours before the next scheduled heparin dose 3.

Common Pitfalls to Avoid

• Using fixed-dose protocols instead of weight-based dosing leads to delayed therapeutic anticoagulation 2, 5
• Capping doses in obese patients results in subtherapeutic anticoagulation for extended periods 8, 9
• Inadequate monitoring frequency in the first 24 hours misses opportunities for timely dose adjustment 3, 7
• Stopping heparin before adequate warfarin effect (INR ≥2.0 for 2 days) risks recurrent thromboembolism 4, 3